TREDEGAR CORPTG
TREDEGAR CORP Stock Compensation Disclosure
As of December 31, 2024, the Company had one stock-based compensation plan that permits the grants of stock options, stock appreciation rights (“SARs”), stock, restricted stock, and stock unit awards. Awards available for grant totaled 725,154 shares at December 31, 2024. Stock options may be granted to purchase a specified number of shares of common stock at a price no lower than the fair market value on the date of grant and for a term not to exceed 10 years. Stock options exercisable totaled 2,327,655 and 3,019,333 shares at December 31, 2024 and 2023, respectively.
A summary of stock options outstanding at December 31, 2024, 2023 and 2022, and changes during those years, is presented below:
| Option Exercise Price/Share | |||||||||||||||||||||||||||||
| Number of Options | Range | Weighted Average | |||||||||||||||||||||||||||
| Outstanding at January 1, 2022 | 3,125,944 | $ | 10.75 | to | $ | 22.49 | $ | 13.82 | |||||||||||||||||||||
| Forfeited and expired | (17,203) | 14.47 | to | 19.64 | 15.33 | ||||||||||||||||||||||||
Outstanding at December 31, 2022 | 3,108,741 | 10.75 | to | 22.49 | 13.81 | ||||||||||||||||||||||||
| Forfeited and expired | (89,408) | 13.78 | to | 19.64 | 19.60 | ||||||||||||||||||||||||
Outstanding at December 31, 2023 | 3,019,333 | 10.75 | to | 22.49 | 13.64 | ||||||||||||||||||||||||
| Forfeited and expired | (691,678) | 10.75 | to | 22.49 | 14.15 | ||||||||||||||||||||||||
| Outstanding at December 31, 2024 | 2,327,655 | $ | 10.75 | to | $ | 16.37 | $ | 13.49 | |||||||||||||||||||||
No options were granted in 2024, 2023 or 2022.
The following table summarizes additional information about stock options outstanding and exercisable at December 31, 2024:
| Options Outstanding at December 31, 2024 | Options Exercisable at December 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Weighted Average | Aggregate Intrinsic Value | Aggregate Intrinsic Value | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Range of Exercise Prices | Shares | Remaining Contractual Life | Exercise Price | Shares | Weighted Average Exercise Price | |||||||||||||||||||||||||||||||||||||||||||||||||||
| $ | 10.75 | to | $ | 16.37 | 2,327,655 | 1.3 years | $ | 13.49 | $ | — | 2,327,655 | $ | 13.49 | $ | — | |||||||||||||||||||||||||||||||||||||||||
There were no stock options exercised in 2024, 2023 or 2022. The grant-date fair value of stock option-based awards vested in 2023 and 2022 was $2.2 million and $5.4 million, respectively. As of December 31, 2024, there was no unrecognized compensation cost related to stock option-based awards.
Restricted stock grants ordinarily vest three years from the date of grant based upon continued employment. The fair value of restricted stock awards is estimated as of the grant date using the closing stock price on that date.
Stock unit awards vest upon the achievement of certain performance targets.
The following table summarizes additional information about unvested restricted stock awards and performance stock units awards outstanding at December 31, 2024, 2023 and 2022:
| Unvested Restricted Stock Awards | Maximum Unvested Restricted Stock Units Issuable Upon Satisfaction of Certain Performance Criteria | ||||||||||||||||||||||||||||||||||
| Number of Shares | Weighted Avg. Grant Date Fair Value/Share | Grant Date Fair Value (In thousands) | Number of Shares | Weighted Avg. Grant Date Fair Value/Share | Grant Date Fair Value (In thousands) | ||||||||||||||||||||||||||||||
| Outstanding at January 1, 2022 | 335,800 | $ | 16.30 | $ | 5,473 | 50,718 | $ | 17.63 | $ | 1,366 | |||||||||||||||||||||||||
| Granted | 301,969 | 11.88 | 3,587 | — | — | — | |||||||||||||||||||||||||||||
| Vested | (144,317) | 15.10 | (2,179) | — | — | — | |||||||||||||||||||||||||||||
| Forfeited | (18,474) | 14.94 | (276) | (50,718) | 17.63 | (1,366) | |||||||||||||||||||||||||||||
| Outstanding at December 31, 2022 | 474,978 | 13.82 | 6,564 | — | — | — | |||||||||||||||||||||||||||||
| Granted | 454,623 | 7.67 | 3,487 | — | — | — | |||||||||||||||||||||||||||||
| Vested | (167,077) | 11.29 | (1,886) | — | — | — | |||||||||||||||||||||||||||||
| Forfeited | (26,445) | 11.60 | (307) | — | — | — | |||||||||||||||||||||||||||||
| Outstanding at December 31, 2023 | 736,079 | 10.68 | 7,861 | — | — | — | |||||||||||||||||||||||||||||
| Granted | 385,159 | 7.25 | 2,792 | — | — | — | |||||||||||||||||||||||||||||
| Vested | (261,941) | 11.94 | (3,128) | — | — | — | |||||||||||||||||||||||||||||
| Forfeited | (87,181) | 8.51 | (742) | — | — | — | |||||||||||||||||||||||||||||
| Outstanding at December 31, 2024 | 772,116 | $ | 8.79 | $ | 6,787 | — | $ | — | $ | — | |||||||||||||||||||||||||
As of December 31, 2024, the unrecognized compensation cost related to non-vested restricted stock awards was $3.4 million. This cost is expected to be recognized over the remaining weighted average period of 1.8 years.
There were no SARs granted in 2024, 2023 or 2022. SARs may be settled in cash upon exercise and therefore are classified as liabilities and included in accrued expenses in the consolidated balance sheet. The fair value of these liability awards is remeasured at each reporting period until the date of settlement. Increases and decreases in stock-based compensation expense are recognized over the vesting period, or immediately, for vested awards.
A summary of SARs outstanding at December 31, 2024, 2023 and 2022, and changes during those years, is presented below:
| Exercise Price/Share | |||||||||||||||||||||||||||||
| Number of SARs | Range | Weighted Average | |||||||||||||||||||||||||||
| Outstanding at January 1, 2022 | 521,601 | $ | 10.75 | to | $ | 16.37 | $ | 13.55 | |||||||||||||||||||||
| Forfeited and expired | (22,914) | 10.75 | to | 16.37 | 14.83 | ||||||||||||||||||||||||
| Outstanding at December 31, 2022 | 498,687 | 10.75 | to | 16.37 | 13.49 | ||||||||||||||||||||||||
| Forfeited and expired | (53,969) | 10.75 | to | 16.37 | 12.78 | ||||||||||||||||||||||||
| Outstanding at December 31, 2023 | 444,718 | 10.75 | to | 16.37 | 13.57 | ||||||||||||||||||||||||
| Forfeited and expired | (110,272) | 10.75 | to | 16.37 | 13.85 | ||||||||||||||||||||||||
| Outstanding at December 31, 2024 | 334,446 | $ | 10.75 | to | $ | 16.37 | $ | 13.48 | |||||||||||||||||||||
About Stock Compensation Disclosures
Stock-based compensation disclosures detail the equity awards granted to employees and executives — including stock options, restricted stock units (RSUs), and performance shares — along with the valuation methods and assumptions used to expense them. This section reveals the true cost of talent retention and the alignment between management incentives and shareholder interests.
Key signals: total unrecognized compensation expense and its expected recognition period signal future earnings headwinds from already-granted awards. For stock options, examine Black-Scholes assumptions — expected volatility, risk-free rate, and expected term — as understating any of these reduces reported compensation expense. Compare stock compensation expense as a percentage of revenue against peers to assess dilution cost. Watch vesting schedules for acceleration clauses tied to change-of-control events. Performance-based awards with undemanding targets may indicate weak governance. Add back stock compensation to operating cash flow to calculate a more conservative free cash flow figure.